Global Exporter & Bulk Supplier of Bendalieva 100 mg Injection

🌍 Introduction

Are you seeking a premier, globally compliant exporter of Bendalieva 100 mg Injection? At Ernest Oncology (a flagship division of Ernest Pharmaceutical Pvt. Ltd.), we specialize in the secure, efficient, and high-standard distribution of critical oncology formulations. We supply Bendamustine Hydrochloride 100 mg injections to hospitals, specialized cancer centers, and pharmaceutical wholesalers across the USA, UK, Australia, and South Africa.

🔬 1. Product Overview: Bendalieva 100 mg Injection

Bendalieva 100 mg Injection contains Bendamustine, a unique cytotoxic agent with both alkylating and antimetabolite properties, providing a dual-action attack against malignant cells.

• Composition: Bendamustine Hydrochloride 100 mg (as a sterile lyophilized powder)

• Therapeutic Class: Alkylating Agent / Cytotoxic Antineoplastic

• Formulation Type: Single-dose vial for intravenous (IV) infusion

• Storage: Store at room temperature (not exceeding $25^\circ\text{C}$). Keep the vial in the outer carton to protect from light.

⚙️ 2. Mechanism of Action

Bendalieva works through a sophisticated mechanism to treat slow-growing blood cancers:

• DNA Cross-linking: As an alkylating agent, it creates intra-strand and inter-strand cross-links between DNA bases.

• Double-Strand Breaks: This structural damage leads to DNA double-strand breaks, which are difficult for cancer cells to repair.

• Apoptosis Induction: The resulting DNA damage triggers cell cycle arrest and programmed cell death (apoptosis).

• Unique Activity: Unlike older alkylators, Bendamustine remains active even in some cells that have developed resistance to other chemotherapy agents.

🏥 3. Therapeutic Indications

Bendalieva 100 mg Injection is clinically indicated for:

• Chronic Lymphocytic Leukemia (CLL): Used as a first-line treatment for patients with CLL.

• Indolent B-cell Non-Hodgkin Lymphoma (NHL): Specifically for patients whose disease has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

• Multiple Myeloma: Often used in combination with other agents for patients who are not candidates for high-dose chemotherapy with stem cell transplant.

⚠️ 4. Administration & Safety Guidelines

• Professional Use Only: Must be administered only by a healthcare professional via Intravenous (IV) Infusion over 30 to 60 minutes.

• Monitoring: Regular monitoring of complete blood counts (CBC) is required due to the risk of myelosuppression.

• Skin Reactions: Infusion site reactions and skin rashes are common; severe cases may require treatment discontinuation.

• Side Effects: Common reactions include nausea, fatigue, vomiting, diarrhea, and low white blood cell counts (neutropenia).